Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Blood disorders

- PMLiVE

New US drug discovery institute partners with Takeda

Tri-Institutional Therapeutics Discovery Institute to cover communicable, chronic and rare conditions

- PMLiVE

Takeda appoints new financial head

François-Xavier Roger brings experience from Sanofi and in telecoms

- PMLiVE

FDA grants priority review to Takeda’s colitis drug

Accelerates review time for vedolizumab

- PMLiVE

Takeda continues Actos resurrection as Alzheimer’s drug

Late-stage trial will see if pioglitazone can delay disease progression

Takeda expands Latin American footprint

Opens new subsidiary in Peru

- PMLiVE

Phase III data raise hopes for Takeda’s vedolizumab

Bowel disease drug shows efficacy in ulcerative colitis and Crohn's disease

- PMLiVE

Astellas poaches new oncology head from Takeda

Claire Thom is named senior VP of global oncology development

- PMLiVE

Boehringer’s first cancer drug leads EMA recommendations

Afatinib recommended for lung cancer under brand name Giotrif

- PMLiVE

Non-amyloid therapies emerging for Alzheimer’s at AAIC

AAIC meeting hears new clinical data from Lundbeck, Baxter, Chiesi and Takeda

- PMLiVE

New formulations of Pralia and Enbrel head list of new drugs in Japan

Regulator backs medicines from Pfizer, Takeda, Daiichi Sankyo, Astellas, Zeria and otsuka

- PMLiVE

Death leads to recall of batch of Takeda’s Rienso in Switzerland

Marketing partner Amag also reports three other hypersensitivity reactions

- PMLiVE

New vortioxetine studies reinforce efficacy in depression

Supports marketing applications from Takeda and Lundbeck

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links